Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | CASR | P41180 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049675 | 0.87 | SMN1; SMN2 (0.51) | HTTKMT2AMEN1CASRALDH1A1 | |
| SCHEMBL14350895 | 0.80 | KMT2A (0.67) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL14289782 | 0.79 | KMT2A (0.58) | HTTKMT2AMEN1ALDH1A1CA2 | |
| SCHEMBL29724988 | 0.79 | CA1 (0.47) | HTTKMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL15012306 | 0.79 | CA1 (0.47) | HTTKMT2ATDP1MEN1ALDH1A1 | |
| SCHEMBL14289775 | 0.77 | PKM (0.70) | KMT2APKMTDP1MEN1KLK7 | |
| SCHEMBL13145698 | 0.77 | WDR5 (0.48) | HTTKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL11754054 | 0.76 | SMN1; SMN2 (0.63) | HTTKMT2APKMMEN1ALDH1A1 | |
| SCHEMBL5722111 | 0.75 | KMT2A (0.56) | KMT2AMEN1ALDH1A1CA2CA12 | |
| SCHEMBL13180237 | 0.75 | KMT2A (0.50) | HTTKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | HTT 4314/4885KMT2A 4032/4885PKM 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.